Background: Schizophrenia is a heterogeneous group of disorders. The familial-sporadic distinction has been considered under a range of genetic models. Research supports a strong association of de novo copy mutations with sporadic schizophrenia. The aim of the study was to determine a more homogenous phenotype for genetic research via comparison of various clinical and socio-demographic variables in familial and sporadic schizophrenia. Methods: A cross-sectional observational design was used. This study included 384 participants with schizophrenia/schizoaffective disorder from an Afrikaner founder population in South Africa that previously participated in genetic research. A comprehensive data capturing sheet was completed from a pre-existing database that contains information obtained from the Diagnostic Interview for Genetic Studies, chronological clinical summary reports and additional sources of information. The study protocol was approved by the Research Ethics Committee from the Faculty of Health Sciences at the University of Pretoria. Logit models were fitted using the backward elimination procedure to investigate relationships where the dependent variable was binary. Odds ratio estimates were calculated for independent variables that were significant in the model. The KruskalWallis test was conducted to compare the means of groups. For cases where there were significant differences a post-hoc test with a Bonferroni correction was done to determine which groups differ significantly. Results: There were 214 familial and 170 sporadic subjects. 279 had a diagnosis of schizophrenia, 66 schizoaffective, bipolar type and 39 schizoaffective disorder, depressive type. 242 were male and 142 female. The age at onset of the primary psychiatric diagnosis, season of birth, co-morbid diagnoses, symptomatology, suicidality history and marital status weren't significantly different when considering the combined schizophrenia/schizoaffective disorder group and its relationship to familiality. Early deviant behaviour was however decreased in the sporadic group. These findings were replicated when analysing schizophrenia independently from schizoaffective disorder. The sporadic schizoaffective disorder, bipolar type did however have a significantly lower age at onset (mean 20.18 versus 25.07 years), 8.8 times more hallucinations, 6.6 times more odd behaviour before the age of 10 and were 2.8 times more likely to be single. The bipolar type also had 2.9 times more suicide attempts as opposed to ideation. This finding wasn't statistically significant. The sporadic schizoaffective group overall was 2.2 times more likely to abuse substances. The depressive type didn't differ significantly with regards to age at onset, season of birth, co-morbidities, early deviant behaviour, symptomatology, suicidality or marital status. Discussion: The combined schizophrenia/schizoaffective group didn't differ significantly, nor did schizophrenia and schizoaffective disorder depressive type when analysed independently. The sporadic schizoaffective bipolar type differed significantly on multiple important variables that suggest a poorer prognosis and increased disease severity. The sporadic schizoaffective bipolar type forms a more homogenous group, with genetic studies hinting at relatively specific genetic risk factors. Studies elucidating the genetic architecture of this group could prove invaluable in clarifying the aetiology of schizophrenia.
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Background: Subclinical psychotic symptoms, known as schizotypy, predict concurrent and future suicidal ideation and acts. Some suggest this relationship reflects the influence of shared environmental risk factors, or that schizotypy and suicidality are both non-specific indicators of severity of psychopathology. However, this artefactual explanation does not account for the heritability of environmental risk factors, the link between schizotypy and more severe expressions of suicidality, or contemporary theories of suicidality. Methods: We tested whether schizotypy has a direct (causal) effect on the development of suicidal thoughts using a Mendelian randomisation analysis to avoid problems of reverse causality, confounding, and measurement error associated with traditional observational studies. In Mendelian randomisation analyses, genetic variants are used as a proxy measure for a phenotype in order to make causal inferences about the effect of the phenotype on an outcome. We used a schizophrenia gene risk score (GRS), a measure of schizophrenia liability, as a proxy measure for schizotypy. Participants (n = 4767) were part of the Philadelphia Neurodevelopmental Cohort, a publicly available resource designed to assess behavioural and biological factors contributing to mental illness in young adults (aged 8-21 University Health Network, University of Toronto Background: Many rare genetic syndromes are known to phenotypically manifest with psychiatric symptoms that can be indistinguishable from primary psychiatric disorders. While the majority of ongoing research in psychiatric genetics has been dedicated to the identification and characterization of genes involved in primary psychiatric disorders, there has been a lack of research to determine the extent to which rare genetic variants contribute to the overall psychiatric disease load. In our study, we aim to investigate the prevalence of clinically well-characterized pathogenic copy number variant (CNV) syndromes that are associated with neuropsychiatric phenotypes in a large schizophrenia patient cohort. Methods: DNA from 348 schizophrenia patients recruited at the Centre for Addiction and Mental Health (CAMH) (Toronto, Canada) was run on the Affymetrix SNP Array 6. 0. CNVs were called using two algorithms (Canary Software and PennCNV) for deletions >200 kb and duplications >500 kb. CNVs called by both algorithms were included in further analysis. All CNVs were individually assessed to determine overlap with known, clinically well-characterized CNV syndromes with the use of the UCSC Genome Browser, DECIPHER GRCh37, and GeneReviews® databases. Results: A total of 861 deletions and 171 duplications were called on 348 schizophrenia patients. In-depth analysis revealed a total of 16 schizophrenia patients with significant deletions. Microdeletions associated with known syndromes that were identified include: 16p11.2-p12.2 (n=1), 16p13.11 (n=3), 17p11.2 (n=2), 22q11.2 (n=5), 1p36 (n=4), and 5q35.3 (n=1). Analysis for pathogenic microduplications is ongoing. Discussion: We observed a greater than expected number of syndromic microdeletions amongst the schizophrenia cohort (16/348, 4.6%), particularly CNVs already hypothesized or known to be associated with neurodevelopmental disorders. Screening for these rare genetic disorders could lead to better understanding of the pathophysiology of psychiatric disorders, as well as the prevalence of these syndromic CNVs within various psychiatric population subtypes. Correctly identifying syndromic CNVs within psychiatric populations can improve patient prognosis. Further analyses will be undertaken to define specific genes contained within the implicated CNV regions to better characterize potential genetic effects on the phenotypic presentation of SCZ patients. patients. The AKT-mTOR pathway is an important signaling cascade associated with long term plasticity and thus may contribute to cognitive dysfunction. This pathway is tightly regulated by differential phosphorylation of key proteins. AKT is a serine-threonine kinase which regulates critical cellular functions like cell survival, proliferation and growth. Prior literature suggests reduced expression of AKT in SZ. mTOR is a kinase that forms 2 distinct complexes-mTORC1 and mTORC2. mTORC1 consists of mTOR, Raptor, GβL, PRAS40 and Deptor proteins. It plays an important role in actin dynamics and acts downstream of AKT. mTORC2 consists of mTOR, Rictor, GβL, Protor, mSin1 and Deptor proteins. It facilitates ribosome biogenesis and protein translation and acts upstream of AKT. Abnormalities in the mTOR complexes can contribute to dysregulated protein synthesis, which has been implicated in SZ. Alterations in the AKT-mTOR cascade, including abnormal phosphorylation of AKT and expression of mTOR complex components, have been suggested as potential mechanisms underlying SZ pathophysiology. Therefore, we hypothesized that protein levels and/or phosphorylation status of key molecules in the AKT-mTOR pathway are altered in SZ. Methods: We used post mortem dorsolateral prefrontal cortex (DLPFC) from 22 matched pairs of SZ and comparison subjects for this study. Using western blot analysis, we measured protein levels of AKT, mTOR, GβL, Raptor, phosphorylated AKT (at S473 & T308) and phosphorylated mTOR (at S2448 & S2481). Results: We found decreased levels of AKT, phosphorylated AKT (at both S473 and T308) and GβL. We also found that the ratio of phosphorylated mTOR (at S2448) to total mTOR was decreased. Discussion: AKT requires phosphorylation at both S473 and T308 for complete activation. It can further regulate the formation of mTORC1 through Rheb. AKT is phosphorylated at S473 by active mTORC2. mTOR phosphorylation at S2448 is required for its activation in both complexes. Our findings that total AKT and its phosphorylated forms are decreased in conjunction with reduced expression of GβL and the ratio of phosphorylated mTOR (at S2448) to total mTOR suggest that the AKT-mTOR signaling pathway is downregulated in SZ DLPFC. Given the importance of this pathway in synaptic plasticity via its regulation of protein translation and cytoskeletal organization, these abnormalities may represent a mechanism underlying cognitive dysfunction in SZ. Future studies will investigate the expression levels of proteins in mTOR complexes and will determine the integrity of mTORC1 and mTORC2 complex formation in SZ.
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